As with native GLP-1, semaglutide acts to stimulate insulin secretion and inhibit glucagon release depending on the blood glucose concentration, leading to improved blood glucose levels together with a reduced risk of hypoglycaemia [1, 2]
In the PIONEER 10 clinical trial, the outcomes of patients on varying doses of oral semaglutide versus dulaglutide were compared and included side effects
Plasma DPP-4 activity ( A , C , E , and G ), plasma TG and AUC over 180 minutes ( B , D , F , and H , left and middle), and plasma levels of active GLP-1 before and 10 minutes after olive oil gavage ( B , D , F ,and H , right) during a lipid tolerance test (LTT) in response to water or a gut-selective (14 g/mouse) or systemic (10 mg/kg) dose of sitagliptin in 5-hour fasted 16- to 19-week-old Dpp4 EC+/+ ( A and B , n = 1117/group), Dpp4 EC/ ( C and D , n = 1226/group), Dpp4 EC+/+ (BMT) ( E and F , n = 78/group), and Dpp4 EC/ (BMT) ( G and H , n = 78/group) mice fed a 45% high-fat (HF) diet for 69 weeks
Together, theyre worth knowing
GLP-1 and metabolic research compounds are used to study incretin signaling, amylin-pathway activity, and newer multi-agonist receptor models